CMS Interoperability and Prior Authorization rule turnaround times take effect

A federal rule finalized in 2024 sets firm deadlines for health plans to decide prior authorization requests for medical services. Under CMS-0057-F, Medicare Advantage organizations, Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, and issuers of qualified health plans on the federally facilitated exchanges must decide standard requests within 7 calendar days and expedited requests within 72 hours, and must give a specific reason when they deny a request ^[3]. The rule was published in February 2024 with an effective date of April 8, 2024, but its compliance timelines phase in over several years ^[3].

The new 7-day standard is a real change from what many plans currently do. Medicaid managed care organizations have been required to issue prior authorization decisions within 14 days for standard requests and 72 hours for expedited requests under existing federal regulation, and the new rule cuts that standard window in half for MCOs while adding, for the first time, a timeline for Medicaid fee-for-service programs, which previously had no federally required deadline ^[1]. A CMS overview describes related requirements taking effect January 1, 2027, when certain CMS-regulated plans must also implement standardized electronic prior authorization systems, called APIs, so providers can submit and track requests electronically instead of by fax or phone ^[2].

The rule carves out an important exception: it excludes drugs covered under the pharmacy benefit ^[3][2]. That matters because GLP-1 medications such as Ozempic, Wegovy, Rybelsus, Mounjaro and Zepbound are almost always billed through the pharmacy benefit rather than the medical benefit, meaning the vast majority of prior authorization requests for these drugs fall outside the new 7-day and 72-hour deadlines ^[3]. A separate CMS proposal, the 2026 Interoperability Standards and Prior Authorization for Drugs rule (CMS-0062-P), was released April 10, 2026, and would begin to address prior authorization standards specifically for pharmacy-benefit drugs, but as a proposed rule it is not yet final or binding ^[2].

Why it matters for patients

For people prescribed GLP-1 drugs for diabetes or obesity, this rule change is unlikely to shorten the wait for a coverage decision in most cases, because that wait almost always runs through the pharmacy benefit, not the medical benefit covered by CMS-0057-F ^[3]. Patients whose GLP-1 prescriptions happen to be processed under a medical benefit, or who are dealing with prior authorization for other medical services and items, may see faster decisions and clearer denial explanations once the rule's deadlines apply to their plan ^[3].

Prior authorization delays and denials are not a small issue. A 2023 survey of insured adults across Medicaid, Medicare, exchange, and employer coverage found that 16% had experienced a prior authorization problem in the past year, sometimes resulting in delayed or denied care and a decline in health ^[1]. Separately, CMS has estimated that requesting prior authorizations costs providers between $20 and $50 per hour and takes an average of 13 hours per week, or roughly $34,000 and 700 hours of administrative time annually per provider ^[2]. Those administrative burdens can indirectly affect how quickly a GLP-1 prescription gets processed, even though the new federal deadlines do not directly apply to most pharmacy-benefit requests.

What happens next

CMS-regulated plans must implement standardized electronic prior authorization APIs by January 1, 2027 ^[2]. The separate proposed rule addressing prior authorization standards for pharmacy-benefit drugs, CMS-0062-P, was released for public comment on April 10, 2026, and its provisions are not yet finalized, so it is not yet known when, or whether, GLP-1 prior authorizations will be subject to similar turnaround requirements ^[2].